Video

Safety, efficacy of KPI-121 0.25% for DED treatment

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|AAO

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of dry eye disease in patients enrolled in four trials.

See more AAO coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
Related Content
(Image credit: AdobeStock/upnowgraphics) Ophthalmology Times: AMD, AI, and the future of eye imaging: Inside the 2025 International SPECTRALIS Symposium
June 9th 2025

AMD, AI, and the future of eye imaging: Inside the 2025 International SPECTRALIS Symposium

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Ophthalmologists present data on perfluorohexylactane eye drops
June 6th 2025

Ophthalmologists present data on perfluorohexylactane eye drops

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease
May 29th 2025

FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease

Iolyx Therapeutics reports phase 2 results for ILYX-002 in autoimmune-associated dry eye disease
May 27th 2025

Iolyx Therapeutics reports phase 2 results for ILYX-002 in autoimmune-associated dry eye disease

© 2025 MJH Life Sciences

All rights reserved.